ReviewVirology journal2025
Exploring co-infection dynamics and immune response interactions between COVID-19 and Monkeypox: implications for disease severity, viral transmission, and vaccine efficacy.
Review in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- COVID-19 and MPXV: Twindemic Response and Dual Infections in Individuals in a US Metro.Epidemiologia (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus disease (COVID-19) and Monkeypox (Mpox) are viral infections that have similar modes of presentation, diagnosis and treatment strategies. Understanding their co-infection dynamics and immune response is important for public health policies.
aimThis article aims to determine the relationship between dynamicity and immune response interactions between Mpox and COVID-19, focusing more on the implications for disease severity, viral transmission, and vaccine efficacy. METHODOLOGY: An extensive literature review was conducted through electronic databases including PubMed, Google Scholar and Web of Science from the last decade (2014-2024) using keywords: COVID-19, Co-infections, Immune response, Monkeypox, and Vaccination.
resultsSeveral co-infections between COVID-19 and Mpox have been reported, especially a case from Florida, in the United States of America (USA), in Barcelona, Spain (a 56-year-old man who suffered both Mpox and COVID-19 and syphilis simultaneously, and from Italy (a 36-year-old male). Both COVID-19 and Mpox have been shown to have some effects on the immunity of a person, especially the innate system, which can occasionally produce inadvertent effects. A common factor that links the two diseases is the endoglycosidase named Heparanase (HPSE). Both COVID-19 and Mpox clinical features have bizarre severity and complications. The rising co-infection of COVID-19 and increased Mpox infection rate has led to the development of only approved vaccines JYNNEOS and COH04S1.
conclusionGlobal efforts such as adequate awareness campaigns through webinars, social media platforms, and research, including experimental studies, cohort studies, case series, etc., should be put in place to give more insights into both diseases. Such efforts should be backed up with good political will, adequate funding, the establishment of research facilities and interprofessional measures among the concerned countries and policymakers in the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.